At 36.8x earnings and 28.8x forward earnings, BCPC is priced as a quality compounder, not a bargain cyclical. The 4.2 forward PEG ratio signals that growth is not keeping pace with valuation, which weakens the GARP argument at current levels. However, an Altman Z-Score of 9.9 and a Piotroski F-Score of 8 indicate exceptional balance sheet safety and operational strength, meaning insolvency risk is negligible and financial quality is high. This is not a distressed mispricing — it’s a premium multiple on a fundamentally sound but moderately growing specialty chemical operator.